News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC
Jan 17, 2025, 17:53

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared on X:

“Intermittent or Continuous FOLFIRI + PANITUMUMAB RAS and BRAF Wild-Type Metastatic CRC: The IMPROVE Trial

Intermittent FOLFIRI + pani has similar outcomes in terms of PFSot and OS compared to continuous Rx. Detrimental effect in Right sided tumors.”

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Authors: Antonio Avallone, Francesco Giuliani, Alfonso De Stefano, Giuseppe Santabarbara, Guglielmo Nasti, Vincenzo Montesarchio, Gerardo Rosati, Antonino Cassata, Silvana Leo, Carmela Romano, Emiliano Tamburini, Lucrezia Silvestro, Claudio Lotesoriere, Anna Nappi, Daniele Santini, Antonella Petrillo, Alfredo Colombo, Antonio Febbraro, Alessandra Leone, Francesco Mannavola, Maria Maddalena Laterza, Francesco Izzo, Alberto Sobrero, Paolo Delrio, Diana Giannarelli, and Alfredo Budillon.

Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC

 

Akhil Santhosh Alberto Sobrero Alessandra Leone Alfonso De Stefano Alfredo Budillon Alfredo Colombo Anna Nappi Antonella Petrillo Antonino Cassata Antonio Avallone Antonio Febbraro cancer Carmela Romano Claudio Lotesoriere Daniele Santini Diana Giannarelli Emiliano Tamburini Francesco Giuliani Francesco Izzo Francesco Mannavola Gerardo Rosati Giuseppe Santabarbara Guglielmo Nasti Lucrezia Silvestro Maria Maddalena Laterza OncoDaily Oncology Paolo Delrio Silvana Leo Vincenzo Montesarchio
Special Coverage
Blog
Jan 17, 2025, 17:53
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC
Positive
Jan 17, 2025, 17:53
Megan-Claire Chase: For anyone doubting their voice, keep telling your story
Blog
Jan 17, 2025, 17:51
Sabine D. Brookman-May: The Effect of Resistance and/or Aerobic Training on Quality of Life in prostate cancer
Blog
Jan 17, 2025, 17:45
AACR - Cellular Therapies in ALL
Blog
Jan 17, 2025, 17:28
Yale Cancer Center Diversity Enhancement Program in Oncology
Opinion
Jan 17, 2025, 17:21
Senthil Kumar: Systemic Treatment for Advanced/Metastatic Gastrointestinal and Pancreatic Neuroendocrine Tumors
Insight
Jan 17, 2025, 17:20
Advancing Lung Cancer Screening: Insights from Central and Eastern Europe
Insight
Jan 17, 2025, 17:15
Perspectives and Innovation in Pediatric Psycho-Oncology - AIEOP
Blog
Jan 17, 2025, 17:11
The countdown begins for the 17th BGICC - Sharing Progress in Cancer Care
Blog
Jan 17, 2025, 17:03
Hear Her will be an everlasting love of the Florez Lab
Insight
Jan 17, 2025, 16:53
FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer
Insight
Jan 17, 2025, 16:52
Respiratory motion during breathing makes lung tumors difficult to target accurately - P-Cure